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CRISPRi screens reveal a DNA methylationmediated 3D genome dependent causal
mechanism in prostate cancer
Musaddeque Ahmed1,21, Fraser Soares 1,21, Ji-Han Xia2,21, Yue Yang3, Jing Li3, Haiyang Guo1, Peiran Su1,4,
Yijun Tian5, Hyung Joo Lee 6, Miranda Wang1, Nayeema Akhtar1, Kathleen E. Houlahan 4,7,8,9,
Almudena Bosch10,11, Stanley Zhou 1,4, Parisa Mazrooei1,4, Junjie T. Hua1,4, Sujun Chen1,4,7, Jessica Petricca1,4,
Yong Zeng1, Alastair Davies12, Michael Fraser1,7, David A. Quigley13,14, Felix Y. Feng 13,14,15,16,
Paul C. Boutros 8,9,17,18,19, Mathieu Lupien1,4,7, Amina Zoubeidi 12, Liang Wang 5, Martin J. Walsh10,11,
Ting Wang6, Shancheng Ren 3 ✉, Gong-Hong Wei 2,20 ✉ & Housheng Hansen He 1,4 ✉

Prostate cancer (PCa) risk-associated SNPs are enriched in noncoding cis-regulatory
elements (rCREs), yet their modi operandi and clinical impact remain elusive. Here, we perform CRISPRi screens of 260 rCREs in PCa cell lines. We ﬁnd that rCREs harboring high risk
SNPs are more essential for cell proliferation and H3K27ac occupancy is a strong indicator of
essentiality. We also show that cell-line-speciﬁc essential rCREs are enriched in the 8q24.21
region, with the rs11986220-containing rCRE regulating MYC and PVT1 expression, cell proliferation and tumorigenesis in a cell-line-speciﬁc manner, depending on DNA methylationorchestrated occupancy of a CTCF binding site in between this rCRE and the MYC promoter. We
demonstrate that CTCF deposition at this site as measured by DNA methylation level is highly
variable in prostate specimens, and observe the MYC eQTL in the 8q24.21 locus in individuals
with low CTCF binding. Together our ﬁndings highlight a causal mechanism synergistically driven
by a risk SNP and DNA methylation-mediated 3D genome architecture, advocating for the
integration of genetics and epigenetics in assessing risks conferred by genetic predispositions.
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rostate Cancer (PCa) is a leading cause of cancer-related
mortality in men and one of the most heritable forms of
cancer1. Genome-wide association studies (GWAS) have
identiﬁed more than 160 risk loci that harbor thousands of SNPs
associated with the risk for PCa, cumulatively explaining ~28% of
the familial risk for PCa2–4. Some of these risk loci are also
associated with aggressiveness of PCa5–8. It is thus imperative
to understand the mechanisms of how these SNPs function and to
translate PCa GWAS ﬁndings to the clinic. Similar to many other
cancer types, about 98% of the PCa risk SNPs are located outside
of coding exons, and thus do not function through altering
protein-coding sequences4,9. In fact, previous studies have shown
that the noncoding risk variants are signiﬁcantly enriched in cisregulatory elements (CREs)9–12. Several noncoding SNPs have
been identiﬁed to alter CRE functions to cis-modulate target gene
expression7,9,13–15. However, systematic functional dissection of
these risk SNP-containing CREs (rCREs) on a genome-wide scale
remains a challenge and is essential for understanding their
clinical impact.
The recent advent of CRISPR/Cas9-mediated genome editing
approaches has made a systematic assessment of CREs possible by
its virtue of high speciﬁcity and scalability. Several studies
recently implemented this approach to functionally dissect targeted CREs16–20. Several variations have been developed to widen
the applicability, including CRISPR interference (CRISPRi). In
this technique, the Cas9 nuclease is mutated to generate catalytically dead Cas9 (dCas9) and fused with a repressor protein, such
as KRAB, to functionally suppress the targeted chromatin
region21. RNA-guided recruitment of dCas9-KRAB beneﬁts not
only from repressing chromatin regions without altering the
DNA sequence but also bypassing the confounding effect of copy
number alterations21–27.
We and other groups have previously identiﬁed hundreds of
rCREs that harbor at least one PCa-associated risk SNP7,9,13.
In this study, we aimed to evaluate the essentiality of these
rCREs in PCa using CRISPRi-mediated loss-of-function
screens. Our screens reveal that rCREs essential for PCa cell
growth are enriched in the gene desert region of 8q24.21. The
8q24.21 region was one of the ﬁrst functionally dissected risk
loci in PCa, which contains many PCa risk SNPs that cumulatively explain 25% of the familial risk for PCa28. The MYC
oncogene in this region is highly expressed and frequently
ampliﬁed in PCa, making it a prime candidate gene to be
linked with inherited PCa risk9,29,30. Despite the large number
of risk SNPs and rCREs in 8q24.21, studies have failed to
identify the clear association of any genotype with MYC
expression31–33, although several reports indicated physical
interaction between rCREs and MYC promoter in cell line
models10,33,34. One of the most essential rCRE identiﬁed in
our screens regulates MYC and harbors the risk SNP
rs11986220, which confers high odds ratio (OR) for PCa
risk13,35,36. Here, we ﬁnd that the interaction between this
rCRE and MYC promoter is disrupted by CTCF deposition at
a site about 10 Kb upstream of MYC transcription start site
(TSS), and this CTCF deposition is DNA methylation
dependent. CTCF is a key regulator of the three-dimensional
(3D) genome architecture37–43, and disruption of CTCFmediated 3D chromatin interactions may lead to dysregulation of neighboring genes in various cancer types38,44–48. In
addition to disrupting the CRE function, our study unveils
that the CTCF deposition at this locus also reduces the causal
effect of rs11986220. This emphasizes the complexity of the
8q24.21 region, which is subjected to multiple CTCF-mediated
looping, and indicates that the MYC-genotype associations are
perhaps heavily 3D genome dependent.
2

Results
CRISPRi screens with tiling sgRNAs identify essential rCREs
in PCa. Despite possessing deﬁned chromatin characteristics,
CREs function in multifaceted mechanisms that makes the systematic identiﬁcation of core functional regions in CREs a major
obstacle. Chromatin accessibility and histone modiﬁcation data
are often exploited to identify CREs, but these data lack the
capacity to pinpoint the functional sequences in CREs, which
makes them a difﬁcult target for designing short guide RNAs
(sgRNAs) in genome editing techniques such as CRISPR/Cas949.
To overcome this, we took an approach to tile the DNase I
hypersensitive (DHS) region with sgRNAs for any particular
CRE. Previously, we performed an integrative multi-omic analysis
and identiﬁed 270 PCa rCREs that harbor at least one PCa risk
SNP9. Here, we developed an algorithm to design tiling sgRNAs
within each rCRE using criteria as previously described50–53, and
selected equidistantly spaced sgRNAs to achieve maximum coverage (see ‘Methods’) (Fig. 1a). We successfully designed sgRNAs
for 260 rCREs with an average of ﬁve sgRNA per 100 bp DNA
(Supplementary Fig. 1a), resulting in a library of 5873 sgRNAs
that tile these rCREs along with ten control promoter and four
DNase I insensitive regions (Fig. 1b; Supplementary Data 1). The
library was packaged into a lentiviral vector, transduced into cells
stably expressing dCas9-KRAB fusion protein, and selected with
puromycin. We performed the experiment in two PCa cell lines—
LNCaP derived V16A, and 22Rv1 cells, each with two replicates.
The population of cells expressing the library was harvested at
day 0, and then again at day 16 under standard culturing conditions. Genomic DNA was extracted from harvested cells and
the frequency of each sgRNA in each sample was analyzed using
high throughput sequencing. The sgRNA counts at each time
point were strongly correlated between the replicates in both cell
lines (Supplementary Figs. 1b, c), suggesting high reproducibility
of the screens.
The degree of essentiality (measures as “depletion score”, see
‘Methods’) of a locus was estimated by calculating the level of
depletion of sgRNAs in day 16 compared to day 0. The cumulative
depletion of sgRNAs targeting control promoter regions of essential
genes (as identiﬁed in Achilles CRISPR/Cas9 screens25,54) was
much higher compared to the 71 sgRNAs targeting randomly
selected DNase I insensitive regions (Fig. 1c). In parallel to the
V16A and 22Rv1 cell lines, we performed similar screens in a nonsmall cell lung cancer cell line, A549, to gauge the cancer-type
speciﬁcity of the PCa rCREs. Across all three cell lines, when all the
regions were ranked in order of their depletion scores, the control
promoters with high depletion scores are of genes that have high
essentiality scores in Achilles CRISPR-Cas9 screens in respective
cells (Fig. 1d and Supplementary Figs. 1d–f; Supplementary Data 2,
3)25. These control promoters are also distinctly separated from the
DNase I insensitive sites, validating the efﬁciency of our screens
(Fig. 1d). When the promoters are ranked in order of their
depletion score in A549 cells, four out of the top ﬁve promoters,
RPS8, POLR2D, POLR1C, and U2AF1, are of housekeeping genes
that are also essential in Achilles CRISPR-Cas9 screens in A549 cells
(Fig. 1d and S1f; Supplementary Data 4). The library control
promoters of genes speciﬁcally associated with PCa biology, AR and
PCAT1, are among the top 18 and three most depleted regions in
V16A and 22Rv1 cell lines, respectively, but are not ranked within
the top 65 regions in A549 cells (Fig. 1d). In fact, the least depleted
control promoter in A549 is PCAT1 (Fig. 1d), which is speciﬁcally
expressed in PCa55. When the statistical signiﬁcance of depletion of
sgRNAs targeting rCREs in all three cell lines was compared, the
two PCa cell lines had a similar distribution of p values distinct
from that in A549 cells (p < 0.0001; Kolmogorov–Smirnov test)
(Supplementary Fig. 1g). Overall, these data suggest that the
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Fig. 1 CRISPRi screening of prostate cancer risk CREs. a Schematic of rCRE selection and sgRNA design. b Distribution of sgRNAs targeting rCREs or
control regions. The barplot in the inset indicates the number of regions in the library. c The cumulative distribution of depletion p-values of sgRNA
targeting control promoter regions that are essential for growth in Achilles DepMap project (orange), sgRNAs targeting non-DNaseI hypersensitive sites
(green), and sgRNAs targeting rCREs (black). Depletion p values were estimated using the tool MAGeCK (see ‘Methods’). d rCREs ranked by their
depletion scores in three cell lines. Promoters of two prostate-speciﬁc oncogenes, AR and PCAT1, are labeled. The panels below the plots indicate the
knockout effects of the control genes on respective cell growth as observed in Achilles DepMap project. e Correlation of LNCaP ChIP-seq signals of several
histone marks with the depletion score in LNCaP-derived V16A cells. P values are estimated using Spearman’s correlation test. The colors of the box
correspond to the correlation coefﬁcient and the * corresponds to the statistical signiﬁcance of correlation test. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.005.
f Linear regression between H3K27ac ChIP-seq signals and CRISPRi depletion score in cell line-speciﬁc manner. The solid lines denote the best ﬁt for the
regression model and the shaded areas denote 95% conﬁdence interval. P value is calculated using linear regression analysis. g Distribution of odds ratio
for PCa conferred by the risk SNPs within library rCREs. The black line denotes OR of risk SNPs in rCREs in the library; the colored lines denote top 25%
rCREs when ranked by their depletion scores in PCa cell lines. The inset plot demonstrates the OR distribution by risk SNPs in bottom 75% rCREs (brown)
and top 25% rCREs in both V16A and 22Rv1 cells (red) normalized by the overall OR distribution of all library risk SNPs. The inset axes are the same as the
main plot axes.

CRISPRi screens were able to successfully identify regions essential
for cellular proliferation.
Highly essential rCREs harbor SNPs conferring higher risk for
PCa. CREs are typically deﬁned by epigenetic modiﬁcations of
nearby histone molecules56. Hence it is important to determine if
essential rCREs can be distinguished from nonessential rCREs by
epigenetic marks. We correlated the depletion scores from
CRISPRi screens in the LNCaP-derived V16A cells with abundance of several histone modiﬁcations as identiﬁed by ChIP-seq
assays in the LNCaP cell line. The depletion scores strongly
correlated with H3K27ac signal that is typically associated with
the active state of a chromatin region (Fig. 1e)57, but not with

H3K4me1 signal, which is a typical mark for enhancer regions
irrespective of activity status58. When comparing the depletion
scores of rCREs with H3K27ac ChIP-seq signal in all three cell
lines, we observed a strong correlation between H3K27ac signal
and depletion scores in a cell line-speciﬁc manner (Fig. 1f).
Each rCRE in our library harbors at least one PCa risk SNP.
Since the genetic risk conferred by each risk SNP varies9,13,59, we
thus examined the association between risk OR and essentiality of
rCREs. When we separate the library rCREs into most depleted in
any PCa cell line and most depleted in both cell lines, we observe
that the SNPs in the most depleted rCREs confer progressively
higher OR for PCa (Fig. 1g). Importantly, the median OR
conferred by SNPs in most depleted rCREs in both PCa cell lines
is signiﬁcantly higher than the median OR conferred by SNPs in
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Fig. 2 The essential rCREs are enriched in 8q24.21 region. a Depletion score of rCREs in V16A and 22Rv1 cells. The blue points indicate the outlier rCREs
in linear regression between the cell lines. The regression coefﬁcient, β, and the p value are calculated using linear regression analysis between the
depletion scores after removing the six outliers. b The essential rCREs are overrepresented in the 8q24.21 region in V16A cells (p = 0.0004, Chi-sq test).
Each circle denotes a library rCRE. The size of the circle is relative to the depletion fold change. See Supplementary Fig. 2 for other cell lines. c ChIP-seq
signals of histone modiﬁcations and three important transcription factors in the rCRE region of chr8:128531465–128532665 in LNCaP and 22Rv1 cells. Risk
SNP rs11986220 is located close to the center of transcription factors binding site. d Overview of p value and fold change at day 16 compared to day 0 of
the individual sliding windows targeting the rCRE chr8:128531465–128532665. The green bars indicate –log2 p values; the red bar indicates fold change of
sgRNAs in day 16 compared to day 0. FC fold change. Depletion p values and fold changes were estimated using the tool MAGeCK (see ‘Methods’).
e Growth of V16A cells in vitro upon suppression of chr8:128531465–128532665 by two independent sgRNAs using dCas9-KRAB system. Data are
represented as Mean ± s.d. (n = 2). f Tumor growth in a V16A-inoculated mouse xenograft upon injection of respective sgRNAs. Data are represented as
Mean ± s.d. (n = 3). P values were estimated using ANOVA test. *** denotes a p value of 0.007. g Growth of 22Rv1 cells upon suppression of this rCRE
using the same sgRNAs by dCas9-KRAB system. Data are represented as Mean ± s.d. (n = 2). Source data are provided as a Source Data ﬁle.

less depleted rCREs (Fig. 1g inset). These data indicate that SNPs
posing a higher risk for PCa tend to be located in CREs that are
highly essential for PCa growth.
The gene desert region of 8q24.21 is enriched with essential
rCREs. Despite being two distinct PCa cell lines, the depletion
scores in the CRISPRi screens in V16A and 22Rv1 were positively
associated (p = 0.0008, linear regression; p = 0.0008, Pearson’s
correlation test; Combined p = 9.3e–69, Empirical Brown’s
method) (Fig. 2a). The overlap of essential rCREs between the
two PCa cell lines is higher than that with A549 (Supplementary
Fig. 1g inset). Applying an outlier test method (see ‘Methods’), we
identiﬁed six rCREs that have differential essentiality between
the two cell lines (Fig. 2a, marked in blue), and ﬁve of them are
located in the gene desert region of 8q24.21. As a matter of fact,
our CRISPRi screen data reveals that 8q24.21 region is signiﬁcantly overrepresented by essential rCREs (p value < 0.05) in
PCa cell lines but not in A549 cells (Fig. 2b and Supplementary
Figs. 2a–c). The 8q24.21 region is one of the ﬁrst dissected risk
loci associated with PCa and is in the vicinity of important
oncogenes including MYC and PVT160–64. Our screens demonstrate that eight out of the ten rCREs in this region are essential in
at least one PCa cell line, whereas none of them are essential in
A549 (Supplementary Fig. 2d). All of the eight essential rCREs are
marked with H3K27ac histone modiﬁcation in LNCaP cells, with
six of them being also marked with H3K4me1 modiﬁcation
(Supplementary Fig. 2e).
The only differential essential rCRE outside of 8q24.21 is
located in 6p21.2 (chr6:41514080–41514480, FOXP4 promoter),
which has a depletion score signiﬁcantly higher in 22Rv1 than in
V16A (Fig. 2a). Further analysis revealed that this rCRE is
abundantly marked with H3K27ac modiﬁcation only in 22Rv1
4

but not in LNCaP cells (Supplementary Fig. 2f). Among the two
rCREs in the 8q24.21 region with signiﬁcantly higher depletion
scores in 22Rv1 compared to V16A cells, the one at
chr8:128112295–128112695 has a FOXA1 binding speciﬁc to
22Rv1 cells (Supplementary Fig. 2g). The other rCRE at
chr8:12802795–128028315 is located in the intron (~3 Kb downstream of TSS) of PCAT1 (Supplementary Fig. 2h), the promoter
of which confers higher essentiality in 22Rv1 (ranked 2nd
amongst all screened regions) than V16A (ranked 18) cells
(Fig. 1d). Among the three rCREs conferring higher essentialities
in V16A compared to 22Rv1 cells, two are located closely in the
region of chr8:128103955–128105195, which harbors a strong AR
binding site speciﬁcally in LNCaP but not in 22Rv1 cells
(Supplementary Fig. 2g). The rCRE chr8:128531465–128532265
has similar H3K27ac level, as well as binding of multiple
transcription factors, including AR, FOXA1, and HOXB13 in
both cell lines (Fig. 2c); hence, we focus on this rCRE for further
investigation.
rs11986220-containing rCRE promotes cell line-speciﬁc
proliferation and transcriptional changes via modulating
MYC expression. There are 24 100 bp sliding windows (see
‘Methods’) containing at least two sgRNAs targeting the
chr8:128531465–128532265 rCRE, and most of them show strong
depletion in V16A but not in 22Rv1 or A549 cells (Fig. 2d).
We performed validation experiments by targeting this rCRE
using dCas9-KRAB complex guided by two independent sgRNAs
and measured the cell growth rate in vitro. Both sgRNAs resulted
in a decrease in the proliferation of V16A cells (Fig. 2e). To
further investigate the effect of this rCRE in vivo, we injected
mice with V16A cells stably expressing dCas9-KRAB complex
along with sgRNAs against the rCRE or Luc control. A marked
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Fig. 3 The rCRE chr8:128531465–128532265 regulates MYC in V16A but not in 22Rv1 cells. a The top two tracks demonstrate the H3K27ac ChIP-seq
signal in LNCaP and V16A cells. The arc track represents the interactions between this rCRE and neighboring promoter regions as determined by ENCODE
POLII 5C data in LNCaP cells. The intensity of the arc color represents the interaction strength. The bottom track represents the RefSeq gene annotation.
The chromosomal positions are of the genome assembly Hg19. b Expression of neighboring genes as determined by RNA-seq upon repression of the rCRE
chr8:128531465–-128532665 by dCas9-KRAB in V16A cells. The data are shown in mean ± s.d. (n = 2). Source data are provided as a Source Data ﬁle.
c Gene set enrichment analysis shows that the hallmark MYC target genes (MSigDB H collection) are most overrepresented among the genes
downregulated by repression of the MYC promoter (upper panel) or rs11986220-CRE (lower panel). See Supplementary Fig. 3 for overall gene set
enrichment analysis. d Changes in transcriptome-wide gene expression upon repression of the rCRE (by sgCRE) and the MYC promoter region (by sgMYC)
in V16A and 22Rv1 cells. Only the genes differentially expressed (FDR < 0.1 and fold change >1.5, negative binomial test) upon MYC promoter repression
(sgMYC) in dCas9-KRAB V16A cells are shown. The genes are sorted by fold change in V16A cells. FC fold change. e Expression of neighboring genes as
determined by RNA-seq upon repression of the rCRE by dCas9-KRAB in 22Rv1 cells. The data are shown in mean ± s.d. (n = 2). Source data are provided as
a Source Data ﬁle.

decrease in tumor growth was observed upon repression of this
rCRE (Fig. 2f). Importantly, consistent with our screen results in
22Rv1 cells, these sgRNAs did not cause an obvious effect on the
proliferation of 22Rv1 cells (Fig. 2g).
This rCRE harbors two PCa-associated risk SNPs—rs11986220
and rs10090154 (Supplementary Fig. 3a) that are polymorphic for
A/T and T/C alleles, respectively. These SNPs are in high linkage
disequilibrium in major ethnic populations (Supplementary
Fig. 3a)13,36. Several genome-wide association analyses have
found the minor allele A of rs11986220, or T of rs10090154, to be
highly associated with PCa risk across multiple ethnic populations, conferring OR of 1.19–3.4513,35. In LNCaP and 22Rv1 cells,
this rCRE is marked by H3K27ac and has a strong binding of AR,
FOXA1, and HOXB13, all of which are critical transcription
factors for PCa biology (Fig. 2c). A similar level of H3K27ac
modiﬁcation was also observed in V16A cells (Fig. 3a). Since the
SNP rs11986220 is located near the center of the binding sites
(Supplementary Fig. 3a), we used IntraGenomic Replicates
analysis to predict the effect of the genotype of this SNP on

transcription factors binding15. Consistent with previous
reports13, the risk allele A of rs11986220 is associated with a
signiﬁcantly higher level of FOXA1 binding (Supplementary
Fig. 3b). Furthermore, among the cancer cell lines in ENCODE,
this chromatin region is accessible only in PCa cell
line (Supplementary Fig. 3c). The speciﬁcity of this rCRE to the
prostate tumor and its activation by androgen13 emphasize
the importance of this rCRE in prostate transformation.
Next, we sought to identify the underlying functional
mechanism of the rs11986220-containing rCRE. Chromosome
Conformation Capture Carbon Copy (5C) anchoring at Pol II
binding sites in LNCaP cells revealed that this rCRE interacts
with four nearby genes, showing the strongest interaction with
the MYC promoter (Fig. 3a). Consistent with the 5C data, a
Chromosome Conformation Capture (3C) analysis also detected
the interaction between this rCRE and MYC promoter in LNCaP
cells33. This indicates that this rCRE may function as an MYC
enhancer in PCa. To validate, we designed pairs of sgRNAs each
targeting the rs11986220-containing rCRE, two negative controls,
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and the MYC promoter (Supplementary Fig. 3d; Supplementary
Data 5). When transduced into V16A cells stably expressing
dCas9-KRAB complex, sgRNAs targeting the rCRE signiﬁcantly
reduced the mRNA expression of MYC (Supplementary Fig. 3e).
To assess the effect of this rCRE on the transcriptome, we
performed RNA-seq in these cells upon repression of the rCRE
(sgCRE) and MYC promoter (sgMYC). Amongst the genes in the
vicinity, only MYC and PVT1 expression was markedly reduced
(fold change = 0.49 and 0.7, respectively) upon repression of this
rCRE in V16A cells (Fig. 3b). Gene set enrichment analysis
identiﬁed the MYC-regulated gene set to be most enriched
amongst sgMYC target genes. The same MYC-regulated gene set
was also the most enriched amongst sgCRE target genes (Fig. 3c
and Supplementary Figs. 3f, g). At the transcriptome level, 912
genes were found differentially expressed upon suppression of the
rs11986220-containing CRE, 67% of which were also found
differentially expressed upon suppression of MYC promoter
(Supplementary Fig. 3h). The effects of the rs11986220containing rCRE and MYC promoter repression on the RNA
expression of target genes were strongly correlated (Pearson’s
correlation coefﬁcient = 0.94, p = 2.2E–16) in V16A cells,
indicating this rCRE mainly function through regulating MYC
transcription (Fig. 3d).
In contrast to V16A cells, the rs11986220-containing rCRE
is not found to be essential in 22Rv1 cells (Fig. 2g). However, this
rCRE exhibits chromatin occupancy characteristic in 22Rv1 cells
with AR, FOXA1, and HOXB13 binding and marked by H3K27ac
and H3K4me1 modiﬁcations similar to that in LNCaP cells
(Fig. 2c). Since this rCRE primarily regulates MYC, its nonessentiality in the 22Rv1 cells could be explained if MYC was not
essential for 22Rv1 cell growth; however, repression of MYC
signiﬁcantly inhibits proliferation of 22Rv1 cells (Supplementary
Fig. 3i). An alternative explanation is that the rs11986220containing rCRE regulates some other genes that are not essential
for the growth of 22Rv1 cells. To test that, we performed RNAseq in 22Rv1 cells upon repression of this rCRE and MYC
promoter using the same guide RNAs as used in V16A cells.
While the effect of sgMYC on RNA expression of the target genes
are similar between 22Rv1 and V16A cells, sgCRE treatment did
not signiﬁcantly alter the expression of any genes in 22Rv1 cells
(Fig. 3d, e and Supplementary Fig. 3j). All these data indicate that
despite having similar epigenetic characteristics as in LNCaP cells,
the regulation on MYC expression by this rCRE is somehow lost
in 22Rv1 cells.
CTCF binding near MYC mediates rCRE and MYC promoter
interaction. Since promoter–CRE interaction is a spatial
arrangement in 3D genome space, we performed Hi-C assay in
both V16A and 22Rv1 cells to better understand the 3D genome
architecture in these cell lines. The Hi-C data reveals that the
rs11986220-containing rCRE interacts with MYC promoter in
V16A cells but not in 22Rv1 cells (Fig. 4a). This suggests
that 22Rv1 cells have a different 3D conformation than the
V16A cells, which restricts the physical interaction between
the rCRE and MYC promoter. A cell’s 3D chromatin structure
is inﬂuenced by the protein CTCF37,38, and promoter–CRE
interaction is usually encompassed by CTCF-mediated
chromatin looping39,40,65,66. Several studies have reported that
CTCF may form insulator loops blocking functions of
nearby CREs38,39,44–48,67,68. Analyzing the CTCF ChIP-seq data
in several PCa cell lines, we detected two CTCF-binding
sites between the rs11986220-containing rCRE and MYC
promoter—one is 10.4 Kb upstream (chr8:128737774–128738489;
referred to as “–10 Kb” locus hereafter) and another 2.2 Kb
upstream (chr8:128745980–128746790; referred to as “–2 Kb”
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locus hereafter) of MYC TSS (Fig. 4b). Between the two, CTCF
binding is variable across PCa cell lines only at the –10 Kb locus,
whereas 22Rv1 cells have almost fourfold higher binding than in
LNCaP cells (Fig. 4b). The –2 Kb locus has been recently reported
as a conserved and constitutive CTCF binding site with an
enhancer-docking function to promote MYC expression69. We
thus hypothesized that the higher CTCF binding at the –10 Kb
locus in 22Rv1 cells blocks the MYC promoter–CRE interaction.
To test this hypothesis, we generated two clonal variants of 22Rv1
—22Rv1Δ–10 Kb and 22Rv1Δcontrol, by expanding single-cell
clones upon deletion of the –10 Kb locus and a neighboring
control region, respectively, using CRISPR/Cas9 system. We then
performed 3C experiments in these variants along with the V16A
cells, and observed strong interaction between the rCRE and
MYC promoter in V16A but not in 22Rv1Δcontrol cells (Fig. 4c), in
consistent with the Hi-C data (Fig. 4a). Depletion of the –10 Kb
CTCF site resulted in strong interaction in 22Rv1Δ–10 Kb similar
to that observed in V16A cells (Fig. 4c). Consistently, MYC
expression was induced by more than twofold in 22Rv1Δ–10 Kb
cells (Fig. 4d).
Thousands of CTCF-binding sites across the genome show
variable binding afﬁnity for CTCF, typically due to variable
methylation levels of CpGs within the binding sites70–72. In
consensus, hypermethylation of CpGs in CTCF-binding motif is
correlated with lower CTCF binding and vice versa70,73–75. The
DNA sequence at –10 Kb locus has a canonical CTCF binding
motif near the summit of the CTCF ChIP-seq peak, and the ﬁrst
CpG in the motif is variably methylated in ENCODE cell lines
(Fig. 4e and Supplementary Fig. 4a). We performed bisulﬁte
conversion followed by Sanger sequencing and determined that
this CpG is highly methylated in V16A, but lowly methylated in
22Rv1 cells (Fig. 4e). On the contrary, the methylation level at
the –2 Kb site is consistently low, consistent with the
constitutively high CTCF binding observed at this locus
(Supplementary Fig. 4a). The effect of CpG methylation at the
–10 Kb motif is evident by the inverse correlation observed
between the methylation level and the CTCF ChIP-seq signals
across the ENCODE cell lines (Spearman’s rho = –0.528; p =
0.017) (Fig. 4f and Supplementary Figs. 4b, c). To further
validate, we coupled dCas9 with the methylating complex
DNMT3A-3L and transfected 22Rv1 cells with sgRNAs targeting the –10 Kb and –2 Kb CTCF-binding sites. We observed that
methylating the –2 Kb locus markedly decreases MYC expression consistent with a previous report69, but methylating the
–10 Kb locus signiﬁcantly increases MYC expression in
22Rv1 cells (Supplementary Fig. 4d).
CTCF regulates the causal function of rs11986220. The SNP
rs11986220 has a high risk OR for PCa among men from multiple
ethnicities13,35,36. Despite the high prevalence of the risk allele A
in the population, studies have failed to associate the SNP genotype with any gene in eQTL analyses in large cohorts (Supplementary Figs. 4e, f)31,33,76. Since the rs11986220-containing rCRE
regulates MYC transcription only in absence of CTCF deposition
at the –10 Kb locus (Fig. 4c, d), the effect of rs11986220 genotype
on MYC expression may be masked by CTCF binding. To
examine the effect of CTCF binding in SNP-gene association, we
obtained the methylation (as a surrogate of CTCF occupancy),
genotype, and RNA abundance data in 128 prostate tissues77.
Similar as observed in the ENCODE data, methylation level at the
–2 Kb site is constitutively low, while that of the –10 Kb site is
highly variable (Fig. 4g). We then dichotomized the 128 samples
based on the methylation level at –10 Kb motif into “High” and
“Low” mCpG groups, and found the rs11986220 to be a strong
eQTL for MYC (regression coefﬁcient = 0.393; p value = 0.009)
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Fig. 4 Methylation-dependent variable CTCF binding at –10 Kb locus regulates MYC eQTL. a Hi-C interaction map in 8q24.21 region in V16A (top-right
triangle) and 22Rv1 cells (bottom-left triangle). The green square denotes the rs11986220-containing rCRE and MYC-promoter boundary and the blue
square indicates the interaction points between these loci. b CTCF ChIP-seq signals in PCa cell lines between the rs1198220-containing rCRE and MYC
promoter. The yellow bar denotes the CTCF binding site 10 Kb upstream of MYC promoter (–10 Kb site) which accumulates almost fourfold more CTCF
deposition in 22Rv1 cells compared to LNCaP cells. c Interaction across chromatin regions between the rCRE and MYC promoter as determined by 3C
assay. The data are shown in mean ± s.d. (n = 3). d Quantiﬁcation of MYC transcripts by qPCR in 22Rv1 cells upon CRISPR/Cas9-mediated deletion of the
–10 Kb CTCF site. Error bars denote standard error of mean (n = 2). e The top track indicates CTCF ChIP-seq proﬁle in two cell lines and the position of
CTCF binding motif (red bar). The motif logo is shown on the second track. The sequences shown are of the reference genome and bisulﬁte converted
genome. The bottom two tracks show Sanger’s sequencing data upon bisulﬁte conversion in V16A and 22Rv1 cells. The red box denotes the differentially
methylated CpG dinucleotide. f Correlation between the methylation level of this CpG and CTCF ChIP-seq signal at this locus in ENCODE cells. Each circle
denotes a cell line and the blue line indicates the regression coefﬁcient. See also Supplementary Fig. 4. g Distribution of methylation level of CpGs in –10 Kb
and –2 Kb sites in 128 prostate tissues as determined by the whole-genome bisulﬁte sequencing. h Association between rs11986220 genotype and MYC
expression in prostate tissues dichotomized by high (left panel) and low (right panel) level of methylation of the CpG in –10 Kb CTCF binding motif. The
lines indicate the best ﬁt for the regression models and the shaded areas indicate 95% conﬁdence interval. The regression coefﬁcient, β, and the p value are
calculated using linear regression analysis. Source data are provided as a Source Data ﬁle.
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only in high mCpG subset but not in low mCpG subset
(regression coefﬁcient = −0.099; p value = 0.332) (Fig. 4h).
After conﬁrming the enhancer-blocking function of CTCF at
–10 Kb site, we further sought to investigate the chromatin
plasticity mediated by this site. In ENCODE CTCF ChIA-PET
data, the –10 Kb site interacts with another CTCF-binding site
~900 Kb downstream of MYC in MCF7 and K562 cells (Fig. 5a).
Both MCF7 and K562 cells have high CTCF deposition at –10 Kb
site comparable to that in 22Rv1 cells (Fig. 5a). Motif analysis
reveals that these two CTCF sites have converging CTCF motifs
that is often observed in interacting CTCF loci38,43 (Fig. 5a). Our
Hi-C data also indicates that these two CTCF-binding sites
indeed interact with each other in 22Rv1 cells, but not in V16A
cells (Fig. 5b). Besides MYC, this cell line-speciﬁc insulator loop
also includes the long noncoding RNA, PVT1 (Fig. 5a). PVT1 is
another critical oncogene, which together with MYC drive
tumorigenesis78. Deletion of the –10 Kb site also dramatically
induces PVT1 expression in 22Rv1 cells (Fig. 5c). Similar to MYC,
rs11986220 genotype has a strong association with PVT1
expression only in prostate tissue samples with high methylation
at –10 Kb site (Fig. 5d). Amongst the expressed genes near MYC
in prostate tissues, MYC expression is strongly correlated with
only PVT1 expression in tissue samples with high methylation,
but the correlation is lost in tissue samples with low methylation
at –10 Kb site (Fig. 5e and Supplementary Fig. 5a). These data
suggest that the CTCF mediated looping blocks rs11986220containing rCRE and disrupts the co-regulation of MYC and
PVT1. The co-regulation of these two genes is critical in cancer
predisposition, as the oncogenic function of MYC is dependent
on PVT1 expression and these two genes drive tumorigenesis
synergistically78,79.
The enhancer-blocking insulator loop mediated by CTCF at
the –10 Kb site thus mitigates the causal function of the PCa risk
SNP rs11986220, and the risk conferred by rs11986220 is
dependent on high methylation or low CTCF binding at the
–10 Kb site (Fig. 5f). In fact, when analyzing the methylation level
at –10 Kb site in ﬁve PCa patients carrying homozygous risk allele
of rs11986220, we observed that the methylation level at –10 Kb
motif is signiﬁcantly higher in tumor compared to adjacent
normal prostate tissues (p = 0.004; Student’s t test) (Supplementary Fig. 5b). Additionally, in our 3C interaction amplicons, we
observed 1.5 fold higher enrichment of the risk allele A of
rs11986220 in 22Rv1Δ–10 Kb cells compared to 22Rv1Δcontrol cells
(Supplementary Fig. 5c). Altogether, this suggests that the risk
allele of rs11986220 and higher methylation at –10 Kb function
synergistically confer greater risk for PCa (Fig. 5f).
Discussion
PCa genetic risk SNPs are enriched in noncoding CREs rather
than in protein-coding regions9,80. It is challenging to systematically evaluate the importance of these rCREs in cancer biology
and the clinic. Our study demonstrates that CRISPRi mediated
loss-of-function screen of rCREs is an efﬁcient approach to
mitigate this challenge. We demonstrate that rCREs essential for
PCa growth are characterized by higher H3K27ac modiﬁcation. It
is worth noting that many of the rCREs are not prostate speciﬁc
and are also essential in lung cancer cell line A549. Identiﬁcation
and characterization of the target genes of these CREs will be of
interest and warrant further investigation. Epigenomic proﬁling
of prostate tissues and tumors is becoming prevalent81–84, which
will be very useful to pinpoint essential rCREs for PCa predisposition and progression. By comparing risk scores of genetic
predispositions with essentiality, we observed that the rCREs
harboring stronger PCa genetic predispositions are more essential
for PCa cell proliferation. In other words, genetic alteration in an
8

essential rCRE puts the individual at a greater risk for PCa, further validating the importance of essentiality screens of rCREs.
However, the CRISPRi technique is limited by the efﬁciency of
individual sgRNAs, affecting the sensitivity of the assay. Furthermore, some cell lines such as LNCaP are challenging to
generate a stable expression of dCas9-KRAB, which we failed to
grow upon transduction. The rCRE screens can be further
improved by using more densely tiled sgRNAs and more efﬁcient
fusion repressors. In addition, more comprehensive epigenomic
proﬁling in screened cell lines will provide opportunities to better
understand the biology underlying the essentiality.
We identiﬁed six rCREs that confer differential essentiality in
V16A and 22Rv1 cells, ﬁve of which demonstrate differences in
histone modiﬁcation and transcription factor binding between
the two cell lines. The underlying mechanisms warrant further
investigation. The rs11986220-containing rCRE in the 8q24.21
region is speciﬁcally essential for the growth of V16A cells, but
not the 22Rv1 cells. Our mechanistic analysis revealed that the
differential essentiality of this rCRE is not because of differences
in enhancer activity but enhancer-blocking CTCF binding at the
–10 Kb locus. The –10 Kb site is about 8 Kb upstream of another
MYC-regulating CTCF site69. These two CTCF sites together add
a layer of complexity to an already convoluted regulatory
mechanism of MYC expression, in that the CTCF at the –2 Kb
site acts as an enhancer-docking site and induces MYC transcription, whereas the CTCF at the –10 Kb site acts as an
enhancer-blocker and suppresses MYC. The MYC-inducing
CTCF at the –2 Kb site is conserved across several tissues, constitutive, and does not vary across tissues69. In contrast, the CTCF
at the –10 Kb site is regulated by variable methylation of CpG in
the CTCF motif. Coincidently, introducing methylation to the
CpG sites in the –2 Kb and –10 Kb loci by dCas9-DNMT3A-3L
resulted in decreased and increased MYC expression, respectively.
The CTCF-binding motif at the –10 Kb site does not contain any
common genetic variant or somatic mutation, which indicates
that the variability of the methylation may be epigenetically
regulated and warrants further investigation.
The 8q24.21 region harbors multiple risk loci, which cumulatively account for 25% of familial risk in PCa28. As the most wellstudied oncogene in this locus, MYC has always been speculated
as to the causal gene in 8q24.21. Although a few studies have
demonstrated physical interactions between rCREs and MYC
promoter in prostate and other cancer types33,34,85,86, no association between risk SNPs genotypes and MYC expression has
been observed31–33,76. Lack of MYC eQTL has thus been a longstanding dilemma in understanding the causal mechanisms in the
8q24.21 region. Our ﬁnding that the rCRE-MYC promoter
interaction is dependent on 3D genome architecture suggests that
the frequent looping observed in 8q24.21 may contribute to the
failure in identifying MYC eQTLs in prostate and other cancer
types. Indeed, when we dichotomize the prostate tissue samples
into high and low methylation groups based on the methylation
level (as a surrogate for CTCF binding) at the CpG in the –10 Kb
CTCF motif, we detected a strong association between
rs11986220 genotype and MYC expression speciﬁcally in the high
methylation group. This indicates that eQTL analysis can be
confounded by intervening enhancer-blocking CTCF looping,
which aligns with the previous reports that SNP-gene associations
are less common in presence of an intervening CTCF binding
site67,87,88. Upon further investigation, we found out that the
rs11986220-containing rCRE also regulates PVT1 transcription in
a similar manner, indicating that this rCRE is a common
enhancer for both MYC and PVT1. A recent study identiﬁed
MYC and PVT1 promoters to compete for the same set of
enhancers in MCF7 cells89. The CTCF–CTCF interaction spanning MYC and PVT1 that we identiﬁed in 22Rv1 cells is also
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Fig. 5 CTCF binding at –10 Kb site regulates both MYC and PVT1. a CTCF binding landscape downstream of MYC. The top four tracks show CTCF ChIPseq signals in four cancer cell lines. The –10 Kb site is highlighted in red. The motif track shows a canonical CTCF-binding motif. The direction of the arrow
indicates the orientation of the motif. The arcs show CTCF interactions between two CTCF binding sites in two cell lines as determined by ENCODE CTCF
ChIA-PET data. b The Hi-C interaction map in V16A (top right triangle) and 22Rv1 (bottom left triangle) cells in this region. The interaction point in black
rectangle denotes the interaction between two CTCF sites as shown in panel (a). c Quantiﬁcation of PVT1 expression in 22Rv1 cells upon deletion of –10 Kb
site by CRISPR/Cas9. Error bars denote standard error of mean (n = 2). P value is estimated using t test. d Association between rs11986220 genotype and
PVT1 expression in prostate tissues dichotomized by high (left panel) and low (right panel) level of methylation of the CpG in CTCF binding motif at –10 Kb
site. The lines indicate the best ﬁt for the regression models and the shaded areas indicate 95% conﬁdence interval. The regression coefﬁcient, β, and the p
value are calculated using linear regression analysis. e Pearson’s correlation coefﬁcient between the expression of MYC and neighboring genes in prostate
tissues dichotomized by the methylation level of the CpG. See Supplementary Fig. 5a for expression of neighboring genes. f Schematic of regulation of
causal mechanism by methylation-dependent CTCF binding at –10 Kb site. Source data are provided as a Source Data ﬁle.
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evident in MCF7 cells in publically available CTCF ChIA-PET
data. Since the enhancers they compete for are all located in PVT1
introns, it is likely that the competition occurs only when the
enhancers upstream of the –10 Kb site are blocked by CTCF
looping. Since the causal function of rs11986220 depends on the
absence of CTCF at the –10 Kb site, the OR (1.6) conferred by the
risk allele of rs11986220 is thus underestimated without considering the methylation status at the –10 Kb site. In addition, the
co-activation of MYC and PVT1 in populations with risk alleles at
rs11986220 and high methylation at –10 Kb site may confer much
greater risk, as knockin of both MYC and PVT1, but not each one
alone, drives tumorigenesis in genetic mouse models78.
In summary, we report CRIPSRi screens of rCREs in PCa and
identify a causal mechanism synergistically driven by a risk SNP
and 3D genome architecture. This led to the identiﬁcation of the
long-sought MYC eQTL in 8q24.21 region speciﬁcally in populations with high methylation at the –10 Kb CTCF site. Considering methylation-regulated variable CTCF binding is
prevalent in the human genome, we believe this is a common
mechanism that may affect many other risk loci. In fact, no eQTL
can be found for about 50% of PCa risk loci90. Furthermore,
epigenome-wide association studies (EWAS) have identiﬁed
methylation levels of thousands of individual CpG sites to be
associated with cancer91,92. Many SNPs, both risk-associated and
not, have been identiﬁed to be associated with methylation levels
of CpG sites in prostate tumors93. The intricate interplay among
genetic, expression, methylation, and 3D structure variations
indicate that incorporating EWAS with GWAS may elucidate the
causal mechanisms of many risk loci. Integration of multi-omics
data has already been proposed to perform better as
biomarkers94,95. Additionally, there is increasing evidence of
inter-individual differential methylation of CpG sites in both
humans and mice96–98. Inter-individual differential methylation
levels of many CpG sites in internal tissues were found strongly
correlated with methylation levels in blood99. This increases the
possibility of detecting risk-associated methylation sites using
non-invasive techniques, such as in blood or plasma cell-free
DNA100. Together, our study unveils a direction to combine
genetic with epigenetic risks, thus expected to lead to a paradigm
shift in current approaches of predisposition assessment.
Methods
Target selection and tiling sgRNA design. The library rCREs were selected from
our previous study (Supplementary Data 6)9. Brieﬂy, 122 prostate cancer riskassociated tag SNPs and 5271 LD SNPs (r2> = 0.8) were identiﬁed in respective
populations (Caucasian, African, and Asian). The 5271 LD SNPs (in 122 loci)
overlap with 270 CREs (deﬁned as DNase I hypersensitive regions in LNCaP cells).
These DNase I hypersensitive sites larger than 400 bp were split into 400 bp
windows. For positive controls, the promoter regions of critical genes were selected
as 400 bp window centering the transcription start sites (TSSs) of genes. The
negative controls were selected as DNaseI non-hypersensitive sites.
We developed a custom python tool, named sgTiler, to design tiling small guide
RNAs (sgRNAs) targeting the rCREs and promoter regions. In brief, the tool ﬁrst
identiﬁes all possible guide RNAs using the PAM sequence. Then the algorithm
estimates the efﬁciency using criteria previously described50–53. The speciﬁcity is
estimated using mapping to the entire genome, and the off-target potential is
estimated by the number of off-target mapping and if mapped to exons or open
chromatin regions. Finally, the tool optimizes the number of sgRNAs per CRE by
declustering and selecting sgRNAs equidistantly spaced across the entirety of the
targeted region. Details of the algorithm can be found in the preprint of the tool101.
Cell lines. 22Rv1 and A549 cell lines were obtained from the American Type
Culture Collection (ATCC® CRL-2505 and ATCC® CCL-185) while HEK293FT
cell line was obtained from ThermoFisher (R70007). The LNCaP-derived V16A cell
line has been previously described102. A549, 22Rv1, and V16A cells were cultured
in RPMI1640 medium with 10% FBS (Wisent) and 1% Penicillin and Streptomycin
(450-201-EL, Wisent). 293FT cells were cultured in DMEM medium containing
10% FBS (080150, Wisent), L-glutamine (25030-081, ThermoFisher), and nonessential amino acids (11140–050, ThermoFisher) supplemented with 500 µg/mL
Geneticin (4727894001, Sigma-Aldrich). All cells were cultured at 37° in 5% CO2.
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All cell lines were authenticated by STR and routinely tested for mycoplasma using
the EZ-PCR mycoplasma Test Kit (20-700-20, Biological Industries).
CRISPRi pooled screening, sequencing, and analysis. sgRNAs were synthesized
as 73-mer oligonucleotides (CustomArray, USA), GAAAGGACGAAACACCGN
NNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATA GCAAGTTAAA
ATAAGGC (N’s denote the sgRNA 19–20 nucleotide target sequence) and
ampliﬁed by PCR as a pool using the following primers: TAACTTGAAAGTATT
TCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCG (Forward) and ACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTA
TTTCTAGCTCTAAAAC (Reverse). The PCR product was puriﬁed and then
cloned in the pLV hU6-sgRNA hUbC-dCas9-KRAB-T2a-Puro (gift from Charles
Gersbach—Addgene plasmid # 71236, one vector system) using BsmBI (R0580S,
NEB). Ligation was performed using the NEBuilder® HiFi DNA Assembly Cloning
Kit (E5520S, NEB) and transformed into an electrocompetent strain (Cat.
11635018, Stbl4; ThermoFisher) to achieve ~300x coverage. Colonies were scraped
off plates using LB and plasmid DNA was extracted (NA0310, Sigma GenEluteTM
HP Plasmid Maxiprep Kit). The library was submitted for NGS to conﬁrm adequate library representation of each sgRNA.
Library virus was generated in HEK293FT cells and each cell line was titrated
with library virus to achieve a low MOI. The MOI was determined as previously
described103,104. Brieﬂy, MOI was determined by infecting ~5–6 million cells
with varying amounts of library virus for 24 h, which were then split into media
with or without puromycin (ThermoFisher; Cat. # A11138-03) for 48–72 h (A549,
3.5 µg/mL; 22Rv1, V16A, 3 µg/mL; LNCaP, 2.5 µg/mL). A ratio between these two
populations was calculated to determine the infection efﬁciency to achieve a MOI
of ~0.3. The amount of library virus was scaled up along with the number of cells to
ensure that on average every sgRNA was represented in ~300 cells. For each screen,
cells were split into triplicates every 3–4 days, and maintained at 300x coverage
throughout the screen. Samples were collected in replicates (n = 2) on day 0 and
day 16 post puromycin selection for genomic DNA analysis. sgRNA inserts were
ampliﬁed by PCR as previously described103 and sequenced on an Illumina
HiSeq 2500.
After sequencing, the fastq ﬁles were ﬁrst converted to fasta ﬁles using a custom
shell script. For each sample, a custom bowtie database was generated by the
command bowtie-build in bowtie suite (version 1.1.2)105. The library sgRNAs were
mapped against the database for each sample using bowtie with the parameter v =
0 and default values for other parameters. Since the functional core of a noncoding
region is harder to predict, assessing essentiality of any CRE using the entire 400 bp
window may reduce the sensitivity of the assay. To address this, each targeted
region in the library was split into 100 bp sliding windows (50 bp offset) ensuring at
least two sgRNAs targets a window. The differential sgRNA abundance was
estimated using the “test” command in the tool MAGeCK106. The 100 bp window
with the lowest p value in each CRE is treated as a representative of the essentiality
of the CRE. For adjacent 400 bp windows, we merge all windows into the most
essential window. The depletion score of each CRE is the “neg.score” as reported by
MAGeCK106. For differential essentiality analysis, we applied a mean-shift outlier
test (Bonferroni p < 0.1) based on Studentized residuals in linear regression. The
test was performed using the outlierTest function in the R package “car” version
3.0.3 (Fox and Weisberg 2011). The depletion p values in V16A and 22Rv1 cells
were combined using the R package EmpiricalBrownsMethod107.
DepMap CRISPR-Cas9 screen data. The loss of function knock-out screens of
thousands of genes for LNCaP and 22Rv1 cells were obtained from the Achilles
DepMap GeCKO 19Q1 project25. For the A549 cells, Achilles DepMap Public
19Q3 data were used. For both datasets, gene_effect.csv ﬁles were downloaded from
the DepMap portal. The ranking of all genes was visualized using R. In the DepMap project, the average dependency score of essential genes was set to −1; so
closer to −1 more essential the gene is.
Chromatin immunoprecipitation and sequencing. Chromatin immunoprecipitation (ChIP) assay was performed using V16A cells. Protein A (88845, ThermoFisher) and G (88847, ThermoFisher) Dynabeads were mixed at a 1:1 ratio, and
preincubated with 6 ug H3K27ac antibody (ab4729) 3 h before immunoprecipitation. Cells were crosslinked by 1% formaldehyde for 10 min and then quenched
with 125 mmol/L glycine. After cold PBS wash, the nuclear fraction was extracted
and sonicated in a water bath sonicator (Diagenode bioruptor). Chromatin lysate
was incubated with antibody-conjugated beads overnight. After washing and
reverse crosslinking, DNA was puriﬁed by phenol–chloroform extraction and
subjected to library preparation using the ThruPLEX DNA-seq Kit (R400428,
Rubicon Genomics) according to the manufacturer’s protocol. Sequencing was
performed at the Princess Margaret Genomics Centre. All ChIP-seq data were
aligned against Hg19 using Bowtie2 version 2.0.5105 and the peaks were called
using MACS2 version 2.0.10 108 in its default setting.
Epigenetic analysis. The H3K27ac, H3K4me1, H3K4me3, AR, FOXA1, and
HOXB13 ChIP-seq signal data in LNCaP, 22Rv1, and A549 were obtained from
Gene Expression Omnibus with accession IDs GSM1249448, GSM1145323,
GSM969571, GSM1069682, GSM1410789, and GSE96652, respectively. All signal
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data were downloaded in the bigwig format. For each rCRE, the highest signal for
each factor was extracted using the R package “rtracklayer” version 1.42.2109. The
correlation between depletion score and ChIP-seq signals was estimated using the
R function “cor.test” and visualized using the R package “corrplot” version 0.84.
The H3K27ac ChIP-seq data for 22Rv1 and A549 cells were obtained from
ENCODE portal with accession numbers ENCFF905QBL and ENCFF256RBI,
respectively. Before performing the regression between depletion score and
H3K27ac signal in cell line-speciﬁc manner, the distribution of H3K27ac signals
was reverse normalized by the orderNorm function of the R package “bestNormalize” version 1.4.2110. The depletion scores were kept unmodiﬁed. The regression analysis was performed using the function “lm” in R.
SNP and essentiality association. The SNPs associated with prostate cancer risk
were obtained from GWAS Catalog (Accession ID EFO_0001663, downloaded on
May 4th, 2019)59. If a rCRE harbors multiple GWAS-derived risk SNP within the
600 bp window, SNP with the highest odds ratio (OR) is retained as representative
of that rCRE. The distribution of OR of SNPs in the library CRE was plotted using
density function in R.
Motif analysis. The positional weight matrix (PWM) for the CTCF motif was
obtained from HOCOMOCO database (v10) using the R package “MotifDb”
version 1.24.1. The motif was visualized using the R package “ggseqlogo” version
0.1. The DNA sequences of CTCF peaks were obtained using the function getSeq in
the R package “Biostrings” version 2.50.2 and R dataset “BSgenome.Hsapiens.
UCSC.hg38”. Motifs were scanned in any given chromatin sequence using the
function matchPWM with at least 75% similarity score in both forward and reverse
direction.
Analysis of CTCF and methylation level at –10 Kb site. To check the variation of
methylation level at –10 Kb and –2 Kb sites, methylation fractions of CpG sites
processed from the whole genome bisulﬁte data were downloaded for 89 cell lines
from the ENCODE portal111,112. For the correlation analysis between CTCF ChIPseq signal and methylation level at –10 Kb site, total methylation fraction was
obtained for the CpG at chr8:127725891 (GRCh38) which is located within the
CTCF binding motif at –10 Kb site. In total, 21 out of the 89 cell lines with
methylation data also had to match CTCF ChIP-seq data. The cell line
EFO:0001196 had low read coverage at chr8:127725891 (total reads <5) hence was
removed from subsequent analyses. The CTCF ChIP-seq signal (i.e., fold change
over background) bigwig track for the 20 cell lines was downloaded from the
ENCODE portal. The largest value for the ChIP-seq fold change over background
was considered as the representative signal for each peak. The neighboring nonbinding site for CTCF was randomly chosen as a site with no CTCF binding in PCa
cell lines at chr8: 126,876,479–126,877,065 (GRCh38; Termed as NBS in Supplementary Fig. 4c). The correlation between the methylation and CTCF binding was
calculated in R.
In ENCODE, 47 samples had matching CTCF ChIP-seq and RNA-seq data.
The processed RNA-seq data for these samples were downloaded from the
ENCODE portal. The correlation was calculated in R. All ENCODE data were
downloaded from https://www.encodeproject.org/.
eQTL analysis. To investigate the effect of CpG methylation at the –10 Kb CTCF
site on MYC eQTL, the 128 prostate tissues were dichotomized by the median
methylation level at this site. A regression analysis was performed using the MYC
expression as dependent variable and genotype of rs11986220 using the lm function in R. Before performing the regression, the expression data were transformed
to a normal distribution by Boxcox transformation with a lambda value of –0.1
using the R package “caret” version 6.0.84. The interaction terms between the
genotype and methylation were plotted using the R package “effects” version 4.1.1.
Epigenome editing by dCas9-3A-3L. 22Rv1 cells were transfected with a dCas9DNMT3A-3L (GFP) construct69 along with 3–5 guides that were cloned into
pLKO5.sgRNA.EFS.tRFP (a kind gift of Benjamin Ebert, Addgene plasmid #
57823). Fourty-eight hours post transfection 30–50 K RFP + /GFP + cells were
sorted and RNA extraction was performed followed by qPCR.
DNA bisulﬁte conversion and targeted PCR. Genomic DNA from V16A and
22RV1 cells was isolated using DNeasy Blood & Tissue Kit (Cat. # 69504) and
treated with RNAse A (EN0531, ThermoFIsher). Hundred nanograms of RNA-free
gDNA was converted using the EZ DNA Methylation-Lightning Kit (ZYMO,
D5030), and bisulﬁte-treated DNA was cleaned up using QIAquick PCR Puriﬁcation Kit (QIAGEN 28106). PCR was performed using region-speciﬁc primers
and ZymoTaqTM PreMix (ZYMO, E2003) to capture the CpG methylation status
(Supplementary Data 5). PCR products were puriﬁed and submitted for Sanger
sequencing using the reverse region-speciﬁc primer.
RNA-sequencing. 22Rv1 and V16A dCas9-KRAB stable cells were transduced
individually with lentiviral particles containing two sgRNAs against the MYC
enhancer, MYC promoter or a non-target region (Luciferase and LacZ). Twenty-

ARTICLE

four hours post transduction, cells were selected with complete medium containing
puromycin for 72 h. Total RNA was extracted using the RNeasy Mini Kit (74106,
QIAGEN) according to manufacturer’s instructions. Following on-column DNase
digestion, RNA-seq libraries were prepared using the TruSeq Stranded mRNA
Library Preparation Kit (RS-122-2101, Illumina). TapeStation (Tape 2200, Agilent
Technologies) was used to assess the quality of the libraries and sequencing was
performed at the Princess Margaret Genomics Centre.
The raw sequencing data were mapped to human genome assembly Hg19 using
TopHat2 version 2.1.0113 in its default setting. The reads per gene were counted
using HTSeq version 0.7.2114 against refGene gene annotation115. The differential
expression analyses were performed using DESeq2 package version 1.22.2 in R116.
The differentially expressed genes were ranked in order of their fold change. The
gene set enrichment analysis on the ranked gene list was performed using GSEA
version 4.0.3 for the Hallmark gene set (H collection) in MSigDB117,118.
Mouse xenograft experiments. All animal experiments were conducted in
accordance with the study protocol 4714, which was approved by the University
Health Network Research Ethics Board and Animal Care Committee. Four to sixweek-old male NOD/SCID were obtained from Princess Margaret Cancer Centre
Animal Research Centre (PMCC ARC) and housed under standard temperature,
humidity, and timed lighting conditions mandated by the committee. Mice were
randomly assigned across three experimental groups and used for xenograft
experiments. In brief, a non-targeting sgRNA (Luciferase) or two individual
sgRNAs targeting the rs11986220-CRE were transduced by lentivirus infection into
V16A dCas9-KRAB stable cells. Following puromycin selection for 3 days, the cells
were collected and washed with PBS. Cells were counted and one million cells were
injected subcutaneously on the ﬂank of each mouse in 0.1 mL of sterile PBS.
CRISPRi sgRNA validation. sgRNA sequences were selected from the pooled
library and cloned into the lentiGuide-Puro vector as previously described104.
Lentiviral particles for each sgRNA were generated as mentioned above and
transduced cells were selected with puromycin for 72 h. The sequences of the
sgRNAs used in validation experiments are listed in Supplementary Data 5.
Real-time PCR. Total RNA was puriﬁed with the RNeasy Mini Kit (QIAGEN, Cat.
# 74106) and DNA was removed by performing on-column DNAse treatment
(QIAGEN, Cat. # 79254). cDNA was reverse transcribed using the High Capacity
cDNA Reverse Kit (4368814, Applied Biosystems). RNA expression was quantiﬁed
using primers listed in Supplementary Data 5 along with PowerUp SYBR Green
Master Mix (Applied Biosystems, Cat. # A25742). The CFX96 Touch Real-Time
PCR Detection System (Bio-Rad) was employed to quantify RNA expression and
all samples were normalized to RPS28. qRT-PCR was analyzed by the 2-ΔΔCT
method.
Cell proliferation assays. Cellular proliferation assays were performed using
methods previously described103. In brief, 2000–3000 cells per well of a 96 well
were seeded (Falcon, Cat. # 353072) and imaged for 7 days using IncuCyte ZOOM
live cell imaging system (Essen BioScience, MI USA). Cellular growth was calculated based on cell conﬂuency (%).
Lentiviral transduction and plasmids. The A549, V16A, and 22Rv1 dCas9-KRAB
stable cell line was generated using the Lenti-dCas9-KRAB-blast plasmid (a gift
from Gary Hon, Addgene plasmid # 89567). Lentiviral particles were generated in
HEK293FT cells using the pMDG.2 and psPAX2 packaging plasmids (gift from
Didier Trono—Addgene plasmids # 12259 and 12260). In brief, A549, V16A, and
22Rv1 cells were transduced for 24 h and selected with 10 or 5 µg/ml of blasticidin
(450-190-WL, Wisent) for 5–7 days. Functional assays were performed to assess
the activity of dCas9-KRAB by transducing stable cells with an sgRNA targeting the
MYC promoter (See Supplementary Data 5). MYC expression levels were quantiﬁed by qPCR using primers listed in Supplementary Data 5. Viral particles containing sgRNAs targeting the MYC enhancer or non-targeting regions (LacZ,
Luciferase, NEG-1, and NEG-2) were also generated using 293FT cells as previously
mentioned.
Generation of CTCF deleted variant in 22Rv1 using CRISPR/Cas9. Pairs of
oligos were used for CRISPR/Cas9 mediated deletion of speciﬁc DNA fragments
(See Supplementary Data 5). sgRNAs were cloned into the lentiCRISPRv2 (a gift
from Feng Zhang, Addgene plasmid # 52961) and lentiCRISPRv2blast (gift from
Brett Stringer, Addgene plasmid # 98293). Third-generation lentivirus vectors were
used for packaging in 293T cell lines. The cells were trypsinized and seeded into 12well plates, and 24 h later medium was replaced with low glucose DMEM containing 10% FBS, 0.1% penicillin, and streptomycin. Cells were transfected with
speciﬁc constructs that have previously described14, pVSVG (envelope plasmid),
pMDLg/pRRE (packaging plasmid), and pRSV-Rev (packaging plasmid) plasmids
by Lipofectamine 2000 reagent (Cat. # L3000015, ThermoFisher). The medium was
replaced 24 h post transfection and the medium containing viral particles was
collected every 12 h. Lentivirus medium was ﬁltered through 0.45 µm ﬁlters and
snap freezing with liquid nitrogen. Target cells were seeded in six-well plates and

NATURE COMMUNICATIONS | (2021)12:1781 | https://doi.org/10.1038/s41467-021-21867-0 | www.nature.com/naturecommunications

11

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21867-0

transduced 16 h later with lentivirus-containing medium. Twenty-four hours post
transduction, the medium was replaced with complete media containing 6 ug/mL
blasticidin (450-190-WL, Wisent) and 3.5 ug/ml puromycin (ThermoFisher).
Single cells were obtained by serial dilution into 96-well plates and positive clones
containing the deletion were examined by PCR followed by Sanger sequencing.

Double deletions. 22Rv1 clones deleted of the CTCF region were transduced with
lentivirus containing pairs of sgRNAs against a control region or the rs11986220CRE (backbone lentiCRISPRv2 and lentiCRISPRv2blast) for 24 h. Following this
incubation, media was replaced with completed media and expanded for 4 days.
Genomic DNA and RNA were extracted simultaneously using the AllPrep DNA/
RNA Mini Kit (80204, Qiagen). Deletion efﬁciency was assessed by PCR using
primers spanning regions upstream/downstream of the deleted regions, while RNA
expression was assessed by qPCR following cDNA conversion (High Capacity
cDNA Reverse Kit, ThermoFisher Cat. # 4368814).

Quantitative analysis of chromosome conformation capture assays. 3C
experiments were performed using methods as previously described119. Brieﬂy, ten
million cells were trypsinized and resuspended in a 10% FBS/PBS buffer. Cells were
ﬁxed by 1% formaldehyde in 10 ml of 10% FBS/PBS buffer for 10 min at room
temperature. The reaction was quenched with ice-cold glycine. Following centrifugation, the pellets were washed with cold PBS and re-suspended in a lysis
buffer (10 Mm NaCl; 10 mM Tris-HCl, pH 7.5; 0.2% NP-40; 1x protease inhibitor).
Nuclear extracts were obtained post centrifugation and HindIII (NEB, R0104S) was
used for genomic DNA digestion. Digestion efﬁciency was assessed by SYBR-qPCR
and only completely digested chromatin DNA was ligated using T4 DNA ligase.
After reverse crosslinking, DNA fragments were puriﬁed by ethanol precipitation.
The concentration of ligated DNA samples was measured by SYBR-qPCR and the
samples were diluted to 100 ng/µL before running TaqMan qPCR. Each TaqMAN
qPCR reaction contained 1 µl sample, 5 µl Quantitech probe PCR mix (QIAGEN),
1 µL 1.5 µM Taqman probe, 1 µL primers, and 2 µL water. Control samples include
14 HindIII sites and all DNA fragments were mixed together. The standard curve
of each primer was generated by serial dilution of the control template and results
were normalized to ERCC3 as control. All the primers for this experiment are listed
in Supplementary Data 5.

Hi-C experiment and analysis. HiC was performed using ARIMA-HiC kit
(ARIMA) and the libraries were obtained with KAPA hyper preparation kit
(KAPA) both using the instructions provided by ARIMA-HiC kit. Brieﬂy, Cells
were lysed in a lysis buffer and crosslinked with formaldehyde at 2% ﬁnal concentration. Five micrograms of crosslinked DNA per sample in duplicates was
digested and biotinylated with the provided pool of enzymes (enzymes A to D) in
separate steps and the digested-biotinylated DNA was puriﬁed by using AMPure
XP beads. DNA was size selected between 200–600 bp using AMPure XP beads.
Provided Enrichment beads were used to enrich biotinylated DNA fragments and
libraries were prepared by using Illumina TruSeq sequencing adapters (Illumina).
The sequencing data was processed using the Hi-C Pro pipeline at it is default
conﬁguration120. The Arima-HiC cutsite ﬁle was generated using the tool digest_genome.py with the value of the parameter –r set as ^GATC G^AATC G^ATTC
G^ACTC G^AGTC. Lastly, in order to prevent substantial unnecessary data loss
the following modiﬁcations were made to the HiC-Pro conﬁguration ﬁle.
LIGATION_SITE = GAATAATC,GAATACTC,GAATAGTC,GAATATTC,
GAATGATC,GACTAATC,GACTACTC,GACTAGTC,GACTATTC,GACTGATC,
GAGTAATC,GAGTACTC,GAGTAGTC,GAGTATTC,GAGTGATC,GATCAATC,
GATCACTC,GATCAGTC,GATCATTC,GATCGATC,GATTAATC,GATTACTC,
GATTAGTC,GATTATTC,GATTGATC
MIN_FRAG_SIZE = 10
MAX_FRAG_SIZE = 100,000
MIN_INSERT_SIZE = 100
MAX_INSERT_SIZE = 1000

Statistical analysis. Throughout the study, continuous variables are presented
using the median and interquartile range. Discrete variables are reported as the
actual number or in percentages. All statistical analyses were performed in R
programming language. For comparative analyses, a p ≤ 0.05 was considered signiﬁcant unless stated otherwise. The differential abundance analyses, either for
sgRNAs or mRNA molecules, were performed using negative binomial tests. Differences between two groups were estimated using two-tailed Student’s t test.
Linear regression was performed to estimate the replicability of the CRISPRi
screens across prostate cancer cell lines. Localized enrichment of essential CREs
was estimated using Chi-squared test. The proliferation/tumor growth upon different treatments was compared using ANOVA test. An eQTL effect size and
statistical signiﬁcance were obtained from the β and p value as determined using
linear regression analysis.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Raw and processed sequencing data are deposited in the Gene Expression Omnibus
(GEO) under the accession “GSE142811”. The H3K27ac ChIP-seq data for LNCaP and
22Rv1 cells were obtained from GEO with the accession IDs “GSM1249448” and
“GSM2827407”, respectively. The H3K27ac ChIP-seq data for A549 cells were obtained
from the ENCODE portal with the accession ID “ENCFF256RBI [https://www.
encodeproject.org/experiments/ENCSR778NQS/]”. The H3K4me1, H3K27me3, AR,
FOXA1, and HOXB13 ChIP-seq data were obtained from GEO with the accession IDs
“GSM1145323”, “GSM969571”, “GSM1069682”, “GSM1410789”, and “GSM2537231”,
respectively. The CTCF motif was obtained from the R package MotifDb (version 1.24.1)
with the ID Hsapiens-HOCOMOCOv10-CTCFL_HUMAN.H10MO.A. The accession
numbers of methylation and CTCF binding data from the ENCODE portal are listed in
the Source Data. For the geneset enrichment analysis, the “H” collection was used from
the MSigDB database (http://software.broadinstitute.org/gsea/msigdb/index.jsp). The
DepMap data were obtained from https://ndownloader.ﬁgshare.com/ﬁles/16757666 and
https://ﬁgshare.com/articles/DepMap_GeCKO_19Q1/7668407 for the DepMap Public
19Q3 and DepMap GeCKO 19Q1 libraries, respectively. CPC-GENE data obtained from
the European Genome-phenome Archive with the accession number EGA:
EGAS00001000900. In order to determine the association between the methylation level
and CTCF binding at –10 Kb site, the WGBS data for the ENCODE samples
UBERON:0001159, EFO:0001086, UBERON:0002046, UBERON:0002369,
UBERON:0000992, EFO:0006711, EFO:0003072, EFO:0001187, UBERON:0001150,
UBERON:0000473, UBERON:0000945, UBERON:0002106, CL:0000182,
UBERON:0008952, UBERON:0002367, UBERON:0004264, UBERON:0001323,
EFO:0002791, EFO:0002067, and CL:0002327 were downloaded from https://www.
encodeproject.org/ﬁles/ENCFF157POM/@@download/ENCFF157POM.bed.gz, https://
www.encodeproject.org/ﬁles/ENCFF005TID/@@download/ENCFF005TID.bed.gz,
https://www.encodeproject.org/ﬁles/ENCFF497IYX/@@download/ENCFF497IYX.bed.
gz, https://www.encodeproject.org/ﬁles/ENCFF216DJL/@@download/ENCFF216DJL.
bed.gz, https://www.encodeproject.org/ﬁles/ENCFF189WPY/@@download/
ENCFF189WPY.bed.gz, https://www.encodeproject.org/ﬁles/ENCFF782JXT/
@@download/ENCFF782JXT.bed.gz, https://www.encodeproject.org/ﬁles/
ENCFF940XWW/@@download/ENCFF940XWW.bed.gz, https://www.encodeproject.
org/ﬁles/ENCFF064GJQ/@@download/ENCFF064GJQ.bed.gz, https://www.
encodeproject.org/ﬁles/ENCFF699RBP/@@download/ENCFF699RBP.bed.gz, https://
www.encodeproject.org/ﬁles/ENCFF715DMX/@@download/ENCFF715DMX.bed.gz,
https://www.encodeproject.org/ﬁles/ENCFF844EFX/@@download/ENCFF844EFX.bed.
gz, https://www.encodeproject.org/ﬁles/ENCFF333OHK/@@download/ENCFF333OHK.
bed.gz, https://www.encodeproject.org/ﬁles/ENCFF366UWF/@@download/
ENCFF366UWF.bed.gz, https://www.encodeproject.org/ﬁles/ENCFF842MHJ/
@@download/ENCFF842MHJ.bed.gz, https://www.encodeproject.org/ﬁles/
ENCFF027KTR/@@download/ENCFF027KTR.bed.gz, https://www.encodeproject.org/
ﬁles/ENCFF219GCQ/@@download/ENCFF219GCQ.bed.gz, https://www.encodeproject.
org/ﬁles/ENCFF843SYR/@@download/ENCFF843SYR.bed.gz, https://www.
encodeproject.org/ﬁles/ENCFF804NTQ/@@download/ENCFF804NTQ.bed.gz, https://
www.encodeproject.org/ﬁles/ENCFF867JRG/@@download/ENCFF867JRG.bed.gz, and
https://www.encodeproject.org/ﬁles/ENCFF699GKH/@@download/ENCFF699GKH.
bed.gz, respectively. The CTCF ChIP-seq signal tracks for the same set of samples were
downloaded from https://www.encodeproject.org/ﬁles/ENCFF402URE/@@download/
ENCFF402URE.bigWig, https://www.encodeproject.org/ﬁles/ENCFF848ZIL/
@@download/ENCFF848ZIL.bigWig, https://www.encodeproject.org/ﬁles/
ENCFF551SXN/@@download/ENCFF551SXN.bigWig, https://www.encodeproject.org/
ﬁles/ENCFF858KCB/@@download/ENCFF858KCB.bigWig, https://www.encodeproject.
org/ﬁles/ENCFF500IGC/@@download/ENCFF500IGC.bigWig, https://www.
encodeproject.org/ﬁles/ENCFF932OWO/@@download/ENCFF932OWO.bigWig,
https://www.encodeproject.org/ﬁles/ENCFF698JTY/@@download/ENCFF698JTY.
bigWig, https://www.encodeproject.org/ﬁles/ENCFF894ZLN/@@download/
ENCFF894ZLN.bigWig, https://www.encodeproject.org/ﬁles/ENCFF744UAL/
@@download/ENCFF744UAL.bigWig, https://www.encodeproject.org/ﬁles/
ENCFF599OCP/@@download/ENCFF599OCP.bigWig, https://www.encodeproject.org/
ﬁles/ENCFF913XZA/@@download/ENCFF913XZA.bigWig, https://www.encodeproject.
org/ﬁles/ENCFF603HTW/@@download/ENCFF603HTW.bigWig, https://www.
encodeproject.org/ﬁles/ENCFF350UER/@@download/ENCFF350UER.bigWig, https://
www.encodeproject.org/ﬁles/ENCFF306NUN/@@download/ENCFF306NUN.bigWig,
https://www.encodeproject.org/ﬁles/ENCFF686GDH/@@download/ENCFF686GDH.
bigWig, https://www.encodeproject.org/ﬁles/ENCFF645MYR/@@download/
ENCFF645MYR.bigWig, https://www.encodeproject.org/ﬁles/ENCFF497MQF/
@@download/ENCFF497MQF.bigWig, https://www.encodeproject.org/ﬁles/
ENCFF991GMN/@@download/ENCFF991GMN.bigWig, https://www.encodeproject.
org/ﬁles/ENCFF799LZZ/@@download/ENCFF799LZZ.bigWig, and https://www.
encodeproject.org/ﬁles/ENCFF592HCJ/@@download/ENCFF592HCJ.bigWig. All other
relevant data supporting the key ﬁndings of this study are available within the article and
its Supplementary Information ﬁles or from the corresponding author upon reasonable
request. A reporting summary for this article is available as a Supplementary Information
ﬁle. Source data are provided with this paper.
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Code availability
The codes to design the tiling sgRNA library is available at https://github.com/
HansenHeLab/sgTiler121.
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